A Study of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs in HIV-1 Infected Patients

Completed · Phase 3

Conditions studied: HIV Infections

In brief

To examine the efficacy of saquinavir SGC (soft gel capsules) in combination with other antiretrovirals in HIV-1 infected patients currently treated with saquinavir HGC (hard gel capsules) measured by the absolute change in plasma HIV-1 RNA during the 24 weeks of study treatment.

Key facts

Study ID

NCT00002374

Run by

Hoffmann-La Roche

People needed

120

Last updated by the study team

2005-06-24

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have:
• Documented HIV infection.
• CD4 > 100 cells/mm3.
• Saquinavir HGC-experienced patients (>= 3 months cumulative therapy).
• Required:
• >= 3 months cumulative saquinavir HGC therapy.

Where it is running

• Pacific Oaks Med Ctr — Beverly Hills, California, United States
• Tower Infectious Diseases / Med Associates Inc — Los Angeles, California, United States
• Community Research Initiative of South Florida — Coral Gables, Florida, United States
• Ctr for Quality Care — Tampa, Florida, United States
• Community Research Initiative of New England — Brookline, Massachusetts, United States
• AIDS Ctr — New York, New York, United States
• Anderson Clinical Research / Inc — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.